It looks like this is the end of the line for BioSante as we know it. After dissapointing results from a phase 3 trial when BioSante's lead drug, LibiGel, failed to beat a placebo, shares cratered and never recovered. Now comes today's news that BioSante will be merging with ANI Pharmaceuticals, with ANI gaining control of the company. This video takes a closer look at the merger and what it means for investors.

Many investors are attracted to BioSante and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.